Baillie Gifford & Co
GMAB icon

Baillie Gifford & Co’s Genmab GMAB Stock Holding History

Baillie Gifford & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$248 – 273
2025
Q2 		$248 Sell
12
-42
-78% -$862 ﹤0.01% 264
2025
Q1 		$1.06K Hold
54
– – ﹤0.01% 265
2024
Q4 		$1.13K Hold
54
– – ﹤0.01% 270
2024
Q3 		$1.32K Hold
54
– – ﹤0.01% 275
2024
Q2 		$1.36K Buy
54
+6
+13% +$170 ﹤0.01% 282
2024
Q1 		$1.44K Sell
48
-2
-4% -$59 ﹤0.01% 286
2023
Q4 		$1.59K Buy
+50
New +$1.57K ﹤0.01% 286

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co's GMAB Position: Q3 2025 in Review

Baillie Gifford & Co sold out of Genmab (GMAB) in Q3 2025, closing a stake of 12 shares — an estimated $248 sold.

Baillie Gifford & Co first reported a position in GMAB in Q4 2023 and held it in 7 quarters. The position peaked at $1.59K in Q4 2023. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Baillie Gifford & Co reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
  • Baillie Gifford & Co sold 12 Genmab shares in Q3 2025, an estimated $248.
  • Baillie Gifford & Co first reported a position in Genmab in Q4 2023 and held it in 7 quarters.
  • Baillie Gifford & Co's Genmab position peaked at $1.59K in Q4 2023.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Baillie Gifford & Co's 13F filing for Q3 2025, filed 31 Oct 2025.